{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:45:40Z","timestamp":1792788340221,"version":"4.5.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","funder":[{"name":"Blaze Biosciences","id":[{"id":"https:\/\/ror.org\/00s78tb81","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND AND OBJECTIVES:<\/jats:title>\n                    <jats:p>This Phase II, investigator-initiated, nonrandomized clinical trial evaluated tozuleristide, a tumor-specific near-infrared fluorescence imaging agent, combined with the Canvas\u00ae imaging system (Blaze Bioscience) to enhance intraoperative visualization of glial tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>Subjects with newly diagnosed, suspected, biopsy-proven, or previously resected high- or low-grade central nervous system tumors received 24 mg (contrast-enhancing glioma) or 36 mg (non\u2013contrast-enhancing glioma) of tozuleristide 1 to 24 hours before surgery. Tumors were visualized intraoperatively using the Canvas imaging system. Biopsies were collected to assess tozuleristide sensitivity and specificity by comparing with histopathology assessment. Extent of resection (EOR), calculated from preoperative and postoperative MRI, was compared with historical controls. Fluorescence did not guide resection, and subjects were not selected for maximal EOR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      Thirty-nine subjects (33 contrast-enhancing, 6 nonenhancing tumors) underwent all study procedures. Fluorescence was observed in 30\/33 contrast-enhancing tumors. Across 191 biopsies, fluorescence showed sensitivity = 0.735, specificity = 0.500, positive predictive value (PPV) = 0.847, negative predictive value = 0.333, and accuracy = 0.685. Residual fluorescence occurred only when total resection was unsafe and showed a nonsignificant negative correlation with EOR (r = \u22120.318). The mean EOR was 90.09% (24 mg tozuleristide) with 12 subjects achieving gross-total resection; 0\/6 nonenhancing tumors fluoresced. Among patients with glioblastoma undergoing repeat resection, exploratory comparison with historical controls showed higher gross-total resection rates in tozuleristide-treated subjects (6\/11 vs 2\/11,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .076); however, fluorescence was not incorporated into surgical decision-making, and these results thus cannot be interpreted toward efficacy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>Tozuleristide demonstrated tumor-specific fluorescence with high sensitivity and PPV at 24 mg. The high PPV suggests that fluorescence may be useful for confirming tumor presence in enhancing gliomas, but the low negative predictive value seen cannot exclude tumor in the absence of fluorescence, particularly in infiltrative margins. A well-controlled Phase III trial is necessary to determine the efficacy of image-guided resection in improving EOR.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1227\/ons.0000000000002203","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:02:11Z","timestamp":1790341331000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Tozuleristide Fluorescence-Guided Resection of Gliomas: Results of a Phase II Investigator-Initiated Study"],"prefix":"10.1227","author":[{"given":"Rachel C.","family":"Fox","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Cedars Sinai Medical Center, Los Angeles, California, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemo","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, California, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam N.","family":"Mamelak","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Cedars Sinai Medical Center, Los Angeles, California, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gomez","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Cedars Sinai Medical Center, Los Angeles, California, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chirag","family":"Patil","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Cedars Sinai Medical Center, Los Angeles, California, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray M.","family":"Chu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Cedars Sinai Medical Center, Los Angeles, California, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Rudnick","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Cedars Sinai Medical Center, Los Angeles, California, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jethro","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Cedars Sinai Medical Center, Los Angeles, California, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliott M.","family":"Sina","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Cedars Sinai Medical Center, Los Angeles, California, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith L.","family":"Black","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Cedars Sinai Medical Center, Los Angeles, California, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristi","family":"Harrington","sequence":"additional","affiliation":[{"name":"Blaze Bioscience, Inc., Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1230-8494","authenticated-orcid":false,"given":"John S.","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Cedars Sinai Medical Center, Los Angeles, California, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"issue":"4","key":"R1-20260925","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamaoncol.2019.6143","article-title":"Association of maximal extent of resection of contrast-enhanced and non-contrast-enhanced tumor with survival within molecular subgroups of patients with newly diagnosed glioblastoma","volume":"6","author":"Molinaro","year":"2020","journal-title":"JAMA Oncol"},{"issue":"1","key":"R2-20260925","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s11060-017-2562-1","article-title":"Impact of removed tumor volume and location on patient outcome in glioblastoma","volume":"135","author":"Awad","year":"2017","journal-title":"J Neurooncol"},{"issue":"23","key":"R3-20260925","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.3390\/cancers16233984","article-title":"Enhancing glioblastoma resection with NIR fluorescence imaging: a systematic review","volume":"16","author":"Mansour","year":"2024","journal-title":"Cancers (Basel)"},{"key":"R4-20260925","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.pdpdt.2016.07.012","article-title":"The effectiveness and cost-effectiveness of intraoperative imaging in high-grade glioma resection; a comparative review of intraoperative ALA, fluorescein, ultrasound and MRI","volume":"16","author":"Eljamel","year":"2016","journal-title":"Photodiagnosis Photodyn Ther"},{"issue":"7","key":"R5-20260925","doi-asserted-by":"crossref","first-page":"e0182034","DOI":"10.1371\/journal.pone.0182034","article-title":"The second window ICG technique demonstrates a broad plateau period for near infrared fluorescence tumor contrast in glioblastoma","volume":"12","author":"Zeh","year":"2017","journal-title":"PLoS ONE"},{"issue":"1","key":"R6-20260925","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1158\/1078-0432.CCR-17-1184","article-title":"Fluorescein-guided surgery for resection of high-grade gliomas: a multicentric prospective phase II study (FLUOGLIO)","volume":"24","author":"Acerbi","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"5","key":"R7-20260925","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S1470-2045(06)70665-9","article-title":"Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial","volume":"7","author":"Stummer","year":"2006","journal-title":"Lancet Oncol"},{"issue":"Suppl 6","key":"R8-20260925","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1093\/neuonc\/noac191","article-title":"Turning on the light for brain tumor surgery: a 5-aminolevulinic acid story","volume":"24","author":"McCracken","year":"2022","journal-title":"Neuro Oncol"},{"issue":"11","key":"R9-20260925","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.3390\/cancers13112540","article-title":"5-ALA fluorescence is a powerful prognostic marker during surgery of low-grade gliomas (WHO Grade II)-experience at two specialized centers","volume":"13","author":"Hosmann","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"5","key":"R10-20260925","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1227\/NEU.0b013e31826d1e6b","article-title":"Gross total resection rates in contemporary glioblastoma surgery: results of an institutional protocol combining 5-aminolevulinic acid intraoperative fluorescence imaging and brain mapping","volume":"71","author":"Schucht","year":"2012","journal-title":"Neurosurgery"},{"issue":"1","key":"R11-20260925","first-page":"vdab047","article-title":"5-Aminolevulinic acid-guided resection improves the overall survival of patients with glioblastoma-a comparative cohort study of 343 patients","volume":"3","author":"Baig Mirza","year":"2021","journal-title":"Neurooncol Adv"},{"issue":"3","key":"R12-20260925","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s11060-024-04693-4","article-title":"Long term follow-up of patients with newly diagnosed glioblastoma treated by intraoperative photodynamic therapy: an update from the INDYGO trial (NCT03048240)","volume":"168","author":"Peciu-Florianu","year":"2024","journal-title":"J Neurooncol"},{"issue":"8","key":"R13-20260925","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.3390\/cancers17081332","article-title":"Current and future applications of 5-aminolevulinic acid in neurosurgical oncology","volume":"17","author":"Chen","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"1","key":"R14-20260925","doi-asserted-by":"crossref","first-page":"9477","DOI":"10.1038\/s41467-025-65227-8","article-title":"DNA methylation patterns facilitate tracing the origin of neuroendocrine neoplasms","volume":"16","author":"Goeppert","year":"2025","journal-title":"Nat Commun"},{"issue":"2","key":"R15-20260925","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/1091581817697685","article-title":"Nonclinical profile of BLZ-100, a tumor-targeting fluorescent imaging agent","volume":"36","author":"Parrish-Novak","year":"2017","journal-title":"Int J Toxicol"},{"issue":"1","key":"R16-20260925","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/bip.22748","article-title":"Chlorotoxin: structure, activity, and potential uses in cancer therapy","volume":"106","author":"Ojeda","year":"2016","journal-title":"Biopolymers"},{"issue":"2","key":"R17-20260925","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.3171\/2013.11.FOCUS13497","article-title":"Near-infrared imaging of brain tumors using the tumor paint BLZ-100 to achieve near-complete resection of brain tumors","volume":"36","author":"Butte","year":"2014","journal-title":"Neurosurg Focus"},{"issue":"1","key":"R18-20260925","doi-asserted-by":"crossref","first-page":"20369","DOI":"10.1038\/s41598-026-50648-2","article-title":"Complementary fluorescence and photoacoustic imaging of tozuleristide in muscle tissue in vitro\u2013 toward optically-guided solid tumor surgery: feasibility studies","volume":"16","author":"Shang","year":"2026","journal-title":"Sci Rep"},{"issue":"9","key":"R19-20260925","first-page":"e210","article-title":"Fluorescence-guided tumor visualization using the tumor paint BLZ-100","volume":"6","author":"Kittle","year":"2014","journal-title":"Cureus"},{"issue":"5","key":"R20-20260925","doi-asserted-by":"crossref","first-page":"637","DOI":"10.3390\/pharmaceutics17050637","article-title":"Agents for fluorescence-guided glioblastoma surgery","volume":"17","author":"Romeo","year":"2025","journal-title":"Pharmaceutics"},{"issue":"Suppl 3","key":"R21-20260925","doi-asserted-by":"crossref","first-page":"iii130","DOI":"10.1093\/neuonc\/now078.17","article-title":"NS-17A phase 1 safety and imaging study of BLZ-100 in pediatric brain tumors","volume":"18","author":"Lee","year":"2016","journal-title":"Neuro Oncol"},{"issue":"4","key":"R22-20260925","doi-asserted-by":"crossref","first-page":"e641","DOI":"10.1093\/neuros\/nyz125","article-title":"Phase 1 safety, pharmacokinetics, and fluorescence imaging study of tozuleristide (BLZ-100) in adults with newly diagnosed or recurrent gliomas","volume":"85","author":"Patil","year":"2019","journal-title":"Neurosurgery"},{"issue":"8","key":"R24-20260925","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"R25-20260925","doi-asserted-by":"crossref","first-page":"e081123","DOI":"10.1136\/bmj-2024-081123","article-title":"CONSORT 2025 statement: updated guideline for reporting randomised trials","volume":"389","author":"Hopewell","year":"2025","journal-title":"BMJ"},{"key":"R26-20260925","doi-asserted-by":"crossref","first-page":"100830","DOI":"10.1016\/j.conctc.2021.100830","article-title":"A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients","volume":"23","author":"Yamada","year":"2021","journal-title":"Contemp Clin Trials Commun"},{"issue":"9","key":"R27-20260925","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.5858\/arpa.2018-0197-OA","article-title":"Real-time visualization of breast carcinoma in pathology specimens from patients receiving fluorescent tumor-marking agent tozuleristide","volume":"143","author":"Dintzis","year":"2019","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"R28-20260925","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1093\/neuros\/nyab106","article-title":"Unexpected binding of tozuleristide \u201ctumor paint\u201d to cerebral vascular malformations: a potentially novel application of fluorescence-guided surgery","volume":"89","author":"Kobets","year":"2021","journal-title":"Neurosurgery"},{"issue":"4","key":"R29-20260925","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1093\/neuros\/nyab257","article-title":"A crowdsourced consensus on supratotal resection versus gross total resection for anatomically distinct primary glioblastoma","volume":"89","author":"Khalafallah","year":"2021","journal-title":"Neurosurgery"},{"issue":"4","key":"R30-20260925","doi-asserted-by":"crossref","first-page":"987","DOI":"10.3171\/2023.7.JNS231170","article-title":"Use of 5-ALA fluorescence\u2013guided surgery versus white-light conventional microsurgery for the resection of newly diagnosed glioblastomas (RESECT study): a French multicenter randomized phase III study","volume":"140","author":"Picart","year":"2024","journal-title":"J Neurosurg"}],"container-title":["Operative Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1227\/ons.0000000000002203","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:02:15Z","timestamp":1790341335000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1227\/ons.0000000000002203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":29,"URL":"https:\/\/doi.org\/10.1227\/ons.0000000000002203","relation":{},"ISSN":["2332-4252","2332-4260"],"issn-type":[{"value":"2332-4252","type":"print"},{"value":"2332-4260","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"assertion":[{"value":"2026-04-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}